search
Back to results

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

Primary Purpose

Bacterial Vaginoses

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Secnidazole
Sponsored by
Lupin Research Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bacterial Vaginoses focused on measuring Adolescents, Vaginal fishy smell, Vaginal itching, off-white milky vaginal discharge

Eligibility Criteria

12 Years - 17 Years (Child)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Are adolescent girls 12-17 years of age.
  2. Are willing and able to give written informed assent with a written informed consent from a parent or legal guardian. (Amendment 01- Assent only if State allowed)
  3. Are in good general health including as confirmed by a medical history and physical examination, with no known medical or mental health conditions that, in the Investigator's opinion, may interfere with study participation.
  4. Willing and able to participate in the study as an outpatient, make required visits to the study center, and comply with all study requirements.
  5. Have a negative urine pregnancy test result prior to study treatment initiation. In addition, female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable or transdermal hormonal contraception, intrauterine device [IUD], double-barrier methods, have a vasectomized partner or abstinence [if the patient becomes sexually active they must use one of the acceptable methods of birth control]). Note: NuvaRing® or any other vaginal ring products are not permitted.
  6. Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria:

    1. Off-white (milky or gray), thin, homogeneous vaginal discharge AND
    2. Vaginal pH > 4.5 AND
    3. Presence of Clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount AND
    4. A positive 10% KOH Whiff test.
  7. Agree to abstain from vaginal intercourse until after the TOC visit.
  8. Agree not to have any vaginal penetration or use of any vaginal products until after the TOC visit (e.g., spermicides, condoms, diaphragms, vibrators, tampons, etc.).
  9. Agree not to use vaginal douches or similar products for the duration of the study.

Exclusion Criteria:

  1. Are pregnant, lactating, or planning to become pregnant during the study.
  2. Are menstruating or have vaginal bleeding at the Baseline Visit (Day 1).
  3. Are menopausal as determined by the Investigator.
  4. Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex or human papilloma virus.
  5. Have active genital lesions, including active Herpes simplex lesions, or other vaginal or vulvar conditions which could confound the interpretation of the clinical response, as determined by the Investigator (patients with genital warts that are not being treated may be enrolled).
  6. Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline Visit (Day 1).
  7. Are using NuvaRing® or any other vaginal ring products.
  8. Have consumed any alcohol within 12 hours prior to treatment with study medication.
  9. Have a history of drug or alcohol abuse within the past 6 months, as determined by the Investigator.
  10. Have participated in any investigational trial within 30 days or six half-lives of the test drug's biologic activity, whichever is longer, before the Baseline Visit (Day 1).
  11. Are participating in any investigational, observational or non-interventional study (either currently or during the study).
  12. Have had previous exposure to SYM-1219 or participation in other clinical trials of SYM-1219.
  13. Have a known allergy to nitroimidazoles (e.g., metronidazole, tinidazole, nimorazole, etc.).
  14. Have a history of an abnormal Pap smear which required cervical biopsy or cervical cauterization within 3 months of the Baseline Visit (Day 1).
  15. Have any history of cervical carcinoma or other carcinomas of the vagina or vulva.
  16. Have any condition that interferes with their ability to understand or comply with the requirements of the study.

Sites / Locations

  • Site 1004 - Investigational Research Center
  • Site 1005 - Investigational Research Center
  • Site 1001 - Investigational Research Center
  • Site 1010 - Investigational Research Center
  • Site 1013
  • Site 1011 - Investigational Research Center
  • Site 1008 - Investigational Research Center
  • Site 1007 - Investigational Research Center
  • Site 1006 - Investigational Research Center

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Single dose Solosec (secnidazole) 2g oral

Arm Description

Solosec 2 grams, oral

Outcomes

Primary Outcome Measures

Clinical Outcome Responder
Defined as patients with resolution of abnormal vaginal , negative 10% KOF WHIFF test, and Clue cells less than 20% of the total epithelial cells
Nugent Score
All patients with a score of 0-3 will be considered normal; scores of 4 and above will considered abnormal.
Investigator Clinical Assessment
Investigator's opinion of the need for additional BV treatment. (Yes/No)
Patient's Continued Clinical Response
Investigator's opinion of the continued clinical response to treatment (Yes/No)

Secondary Outcome Measures

Full Information

First Posted
April 22, 2019
Last Updated
December 16, 2020
Sponsor
Lupin Research Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT03937869
Brief Title
Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV
Official Title
A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
November 28, 2018 (Actual)
Primary Completion Date
November 5, 2020 (Actual)
Study Completion Date
November 5, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lupin Research Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A multi-center, open-label study to evaluate the treatment of one oral dose of 2g Solosec™ (Secnidazole) in adolescent girls with BV
Detailed Description
This is a multi-center, open-label study to evaluate the safety of Solosec in adolescent girls with bacterial vaginosis. Approximately 40 patients will be enrolled. Patients determined to be eligible at the Baseline Visit (Day 1) will receive a single oral dose of Solosec™ granules (containing 2 grams of secnidazole) on Day 1. Patients will return to the site once between Days 7-14 for a "test of cure" (TOC) Visit. A follow-up telephone call will be performed at Days 21-30 to assess the continued clinical response to treatment and adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bacterial Vaginoses
Keywords
Adolescents, Vaginal fishy smell, Vaginal itching, off-white milky vaginal discharge

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single dose Solosec (secnidazole) 2g oral
Arm Type
Other
Arm Description
Solosec 2 grams, oral
Intervention Type
Drug
Intervention Name(s)
Secnidazole
Other Intervention Name(s)
Solosec™
Intervention Description
One dose
Primary Outcome Measure Information:
Title
Clinical Outcome Responder
Description
Defined as patients with resolution of abnormal vaginal , negative 10% KOF WHIFF test, and Clue cells less than 20% of the total epithelial cells
Time Frame
At TOC visit study day 7-14
Title
Nugent Score
Description
All patients with a score of 0-3 will be considered normal; scores of 4 and above will considered abnormal.
Time Frame
At TOC visit study day 7-14
Title
Investigator Clinical Assessment
Description
Investigator's opinion of the need for additional BV treatment. (Yes/No)
Time Frame
At TOC visit study day 7-14
Title
Patient's Continued Clinical Response
Description
Investigator's opinion of the continued clinical response to treatment (Yes/No)
Time Frame
At TOC visit study day 7-14

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
must be adolescent females ages 12-17 years of age
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Are adolescent girls 12-17 years of age. Are willing and able to give written informed assent with a written informed consent from a parent or legal guardian. (Amendment 01- Assent only if State allowed) Are in good general health including as confirmed by a medical history and physical examination, with no known medical or mental health conditions that, in the Investigator's opinion, may interfere with study participation. Willing and able to participate in the study as an outpatient, make required visits to the study center, and comply with all study requirements. Have a negative urine pregnancy test result prior to study treatment initiation. In addition, female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable or transdermal hormonal contraception, intrauterine device [IUD], double-barrier methods, have a vasectomized partner or abstinence [if the patient becomes sexually active they must use one of the acceptable methods of birth control]). Note: NuvaRing® or any other vaginal ring products are not permitted. Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria: Off-white (milky or gray), thin, homogeneous vaginal discharge AND Vaginal pH > 4.5 AND Presence of Clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount AND A positive 10% KOH Whiff test. Agree to abstain from vaginal intercourse until after the TOC visit. Agree not to have any vaginal penetration or use of any vaginal products until after the TOC visit (e.g., spermicides, condoms, diaphragms, vibrators, tampons, etc.). Agree not to use vaginal douches or similar products for the duration of the study. Exclusion Criteria: Are pregnant, lactating, or planning to become pregnant during the study. Are menstruating or have vaginal bleeding at the Baseline Visit (Day 1). Are menopausal as determined by the Investigator. Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex or human papilloma virus. Have active genital lesions, including active Herpes simplex lesions, or other vaginal or vulvar conditions which could confound the interpretation of the clinical response, as determined by the Investigator (patients with genital warts that are not being treated may be enrolled). Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline Visit (Day 1). Are using NuvaRing® or any other vaginal ring products. Have consumed any alcohol within 12 hours prior to treatment with study medication. Have a history of drug or alcohol abuse within the past 6 months, as determined by the Investigator. Have participated in any investigational trial within 30 days or six half-lives of the test drug's biologic activity, whichever is longer, before the Baseline Visit (Day 1). Are participating in any investigational, observational or non-interventional study (either currently or during the study). Have had previous exposure to SYM-1219 or participation in other clinical trials of SYM-1219. Have a known allergy to nitroimidazoles (e.g., metronidazole, tinidazole, nimorazole, etc.). Have a history of an abnormal Pap smear which required cervical biopsy or cervical cauterization within 3 months of the Baseline Visit (Day 1). Have any history of cervical carcinoma or other carcinomas of the vagina or vulva. Have any condition that interferes with their ability to understand or comply with the requirements of the study.
Facility Information:
Facility Name
Site 1004 - Investigational Research Center
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Site 1005 - Investigational Research Center
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Facility Name
Site 1001 - Investigational Research Center
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33161
Country
United States
Facility Name
Site 1010 - Investigational Research Center
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34239
Country
United States
Facility Name
Site 1013
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Site 1011 - Investigational Research Center
City
Bardstown
State/Province
Kentucky
ZIP/Postal Code
40004
Country
United States
Facility Name
Site 1008 - Investigational Research Center
City
Saginaw
State/Province
Michigan
ZIP/Postal Code
48604
Country
United States
Facility Name
Site 1007 - Investigational Research Center
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38104
Country
United States
Facility Name
Site 1006 - Investigational Research Center
City
Frisco
State/Province
Texas
ZIP/Postal Code
75035
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

We'll reach out to this number within 24 hrs